GE Healthcare and ulrich medical announce an Agreement to Offer a Branded Multi-dose Contrast Media Injector in the U.S.
Retrieved on:
Monday, November 28, 2022
Medical Supplies, Medical Devices, Health, Hospitals, Radiology, Pharmaceutical, Gesellschaft mit beschränkter Haftung, Cardiology, Active ingredient, Regulation of tobacco by the U.S. Food and Drug Administration, Agent handling, CGMP, Injection, Radiology, Iodine, Emergency department, Neurology, Record, API, Prevalence, Patient, USD, University of Washington Department of Bioengineering, Radiological Society of North America, Good manufacturing practice, Motion, Oncology, FDA, Diagnosis, Professor, Head, Cerebral angiography, Food, University, Conditional sentence, News, NYSE, Research, Radiopharmaceutical, Thomas Edison, Multimedia, RSNA, Patient safety, GE Healthcare, Insight, CT scan, Ecosystem, Congress, MDR, Medical imaging, Pharmaceutical industry, SQM
GE Healthcare has today announced an agreement with ulrich medical for a GE Healthcare branded contrast media injector in the U.S.
Key Points:
- GE Healthcare has today announced an agreement with ulrich medical for a GE Healthcare branded contrast media injector in the U.S.
- The U.S. contrast media injector market is estimated to grow at 4.3 percent annuallyi between 2022-2030, attributed to its developed healthcare infrastructure and the prevalence of chronic diseases.
- Today, the majority of contrast enhanced CT imaging involves radiology technicians filling a syringe with contrast media prior the injection procedure.
- Marco Campione, Americas General Manager at GE Healthcare Pharmaceutical Diagnostics said: Radiology departments are focused on managing increasing demand and on conserving contrast media.